However, studies employing next generation sequencing (NGS) showed that ESR1 amplification in either primary or metastatic tumor is quite rare, occurring at a rate below 2% [7,22], thus reflecting a minor role in endocrine resistance. Here, ESR1 is linked to metastatic neoplasm.